Please assess the completion status of the following clinical trial:

Trial Title: A Pharmacogenetic Investigation of Antipsychotics in Schizophrenia and Schizophrenia-Like Psychoses

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: None
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent must be obtained~* DSM-IV diagnosis must be one of:~  * schizophrenia~ * schizophreniform~ * schizoaffective~ * delusional disorder~ * brief reactive psychosis~ * psychosis not otherwise specified~* Ethnic origin of both parents must be known~* A minimum of 6 weeks continuous treatment completed with the given antipsychotic, prescribed at least at minimum recommended doses~* Prospectively collected outcome data available (pre-treatment and after at least 6 weeks on treatment)~Exclusion criteria:~* Significant psychiatric or medical co-morbidity including history of:~  * head injury with loss of consciousness~ * seizures~ * neurological disorder~ * mental retardation (DSM-IV)~ * drug or alcohol dependence (DSM-IV)~ * serious physical illness e.g. malignancy, hepatic/renal insufficiency~* Concomitant psychotropic medication that may influence ratings~* Concomitant antipsychotics, antidepressants or mood stabilisers prescribed for \>2 weeks during the antipsychotic treatment period rated

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Olanzapine (Type: None): Subjects treated with olanzapine as part of their routine clinical care
- Risperidone (Type: None): Subjects treated with risperidone as part of their routine clinical care
- Quetiapine (Type: None): Subjects treated with quetiapine as part of their routine clinical care

Based on this trial design, predict the completion outcome and termination type (if applicable).